(Adnkronos) - “Dal punto di vista del versante trombotico ci sono sempre più nuove acquisizioni grazie alle nuove tecnologie di ricerca che identificano in maniera più accurata i fattori di rischio e le modalità possibili di intervento, soprattutto di prevenzione.” Ha detto Giancarlo Castaman, Direttore della SOD Malattie Emorragiche e della Coagulazione dell'Azienda Ospedaliero-Universitaria Careggi di Firenze, al XXVIII Congresso Nazionale della Società Italiana per lo Studio dell’Emostasi e della Trombosi (SISET) a Roma.
Category
🗞
NewsTranscript
00:00It is an extremely stimulating title, considering the tradition of the company, which from the
00:11beginning has always been dedicated to research in the field of blood clotting diseases,
00:18both hemorrhagic and thrombotic, and which has above all cultivated the interest and active
00:27involvement, especially in the younger part, therefore even more productive and motivated,
00:32in following research that has led to progress in the field of knowledge, but also therapeutic
00:39progress for these diseases.
00:41Let's say that during the convention results have been presented and will still be presented,
00:46for example, on gene therapy progress for hemophilia A and hemophilia B, which have been
00:53recently published, and we know that in Italy, for example, a few months ago it was approved
00:59for the treatment of the first gene therapy for hemophilia, so this is an important moment
01:05to make a point on what are the current results of the international trial clinics.
01:10Then we know that new drugs are being made more and more for the treatment of these
01:16patients with hemorrhagic pathologies, which I think are the so-called non-substantive therapies
01:21that replace the load of the treatment with traditional therapies.
01:25From the thrombotic point of view, there are always more new acquisitions thanks to all
01:30the new research technologies, the proteomics, the so-called genomics, and so on, which identify
01:36in a more accurate way the risk factors and also the possible interventions, especially
01:43prevention, for these new data that are highlighted.
01:49The other aspect is that new drugs tend to be more and more effective, but above all
01:54safe from the point of view of the collateral effects, I think especially of the hemorrhagic
01:59risk related to anticoagulant therapies, so this progress is also given to ensure
02:05more and more safety to patients with the quality of treatment of the specific symptom.